The stock of Fortress Biotech Inc (NASDAQ:FBIO) is a huge mover today! About 100,574 shares traded hands or 29.09% up from the average. Fortress Biotech Inc (NASDAQ:FBIO) has declined 39.10% since April 5, 2016 and is downtrending. It has underperformed by 41.06% the S&P500.
The move comes after 6 months positive chart setup for the $112.91 million company. It was reported on Nov, 7 by Barchart.com. We have $6.57 PT which if reached, will make NASDAQ:FBIO worth $206.63 million more.
Analysts await Fortress Biotech Inc (NASDAQ:FBIO) to report earnings on November, 14. They expect $-0.21 EPS, up 50.00% or $0.21 from last year’s $-0.42 per share. After $-0.31 actual EPS reported by Fortress Biotech Inc for the previous quarter, Wall Street now forecasts -32.26% EPS growth.
According to Zacks Investment Research, “Fortress Biotech, Inc. is a biopharmaceutical company. The company is engaged in acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress Biotech, Inc., formerly known as Coronado Biosciences, Inc., is based in NEW YORK, United States.”
More important recent Fortress Biotech Inc (NASDAQ:FBIO) news were published by: Nasdaq.com which released: “Fortress Biotech Forms New Subsidiary, Cellvation, Inc., to Develop Novel …” on November 07, 2016, also Investmentnews.com published article titled: “Biopharmaceutical Fortress Biotech to buy an independent broker-dealer”, Globenewswire.com published: “Fortress Biotech Completes Tender Offer for Shares of National Holdings …” on September 12, 2016. More interesting news about Fortress Biotech Inc (NASDAQ:FBIO) was released by: Globenewswire.com and their article: “Fortress Biotech Presents Positive Data from the Phase 1/2 Study of CNDO-109 …” with publication date: May 18, 2016.
FBIO Company Profile
Fortress Biotech, Inc., formerly Coronado Biosciences, Inc., incorporated on June 28, 2006, is a biopharmaceutical company. The Firm is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. The Company’s sole product candidate is CNDO-109. The Firm is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products. It seeks to acquire and invest in drugs, technologies and operating subsidiaries with growth potential. The Company’s product, CNDO-109, is a lysate (disrupted Closteroviridae (CTV)-1 cells, cell membrane fragments, cell proteins and other cellular components) that activates donor Natural Killer (NK) cells. CTV-1 is a leukemic cell line re-classified as a T-cell acute lymphocytic leukemia (ALL). The Firm holds the license to develop and commercialize CNDO-109 to activate NK cells for the treatment of cancer-related and other conditions, and a non-exclusive license to certain clinical data solely for use in the Investigational new drug (IND) for CNDO-109. The Firm is conducting the Phase I clinical studies of CNDO-109.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.